The effect of magnesium sulfate loading dose in treatment of diabetic ketoacidosis

Investigating the effect of magnesium sulfate loading dose on diabetic ketoacidosis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220928056051N3

Enrollment

Registered

2023-04-26

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic ketoacidosis. Diabetes mellitus due to underlying condition with ketoacidosis

Interventions

Intervention 1: Intervention group: For patients in the intervention group, magnesium sulfate will be injected as a loading dose (4 grams of magnesium sulfate equivalent to 8 ml from a vial of 50% mag

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic ketoacidosis Age between 14-65 years

Exclusion criteria

Exclusion criteria: Hypermagnesemia (magnesium more than 3 mg/dL) Hypomagnesemia (magnesium less than 1.5 mg/dL) Having clinical symptoms of hypermagnesemia including neuromuscular symptoms (loss of deep tendon reflexes, muscle paralysis, apnea) and cardiovascular symptoms Severe renal failure (GFR < 30 ml/min/1.73 m2) Patients with drug poisoning Pregnancy

Design outcomes

Primary

Measure	Time frame
The total dose of prescribed insulin until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The total dose of prescribed potassium until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The length of time it will take time to convert insulin administration from IV to subcutaneous form. Timepoint: Until the third day after the intervention. Method of measurement: Clock.	—

Measure

Time frame

The total dose of prescribed insulin until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The total dose of prescribed potassium until the patient exits from acute phase of diabetic ketoacidosis. Timepoint: Daily until the third day after the intervention. Method of measurement: Vial.;The length of time it will take time to convert insulin administration from IV to subcutaneous form. Timepoint: Until the third day after the intervention. Method of measurement: Clock.

—

Secondary

Measure	Time frame
Prolonged time for patient recovery from acute phase of diabetic ketoacidosis. Timepoint: Until the third day after the intervention. Method of measurement: Clock.;Serum magnesium. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.;Fasting blood sugar. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.	—

Measure

Time frame

Prolonged time for patient recovery from acute phase of diabetic ketoacidosis. Timepoint: Until the third day after the intervention. Method of measurement: Clock.;Serum magnesium. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.;Fasting blood sugar. Timepoint: Before and daily until the third day after the intervention. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Laya Hooshmand

Oroumia University of Medical Sciences

hoshmand.l@umsu.ac.ir+98 44 3345 7286

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026